Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | RRM2 | P31350 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.35 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829134 | 0.84 | ABAT (0.34) | HRH3ADRB2RRM2ABAT | |
| SCHEMBL12927610 | 0.84 | LOXL2 (0.40) | LOXL2HRH3ADRB2RRM2ABAT | |
| SCHEMBL13825298 | 0.84 | LOXL2 (0.40) | LOXL2HRH3ADRB2RRM2ABAT | |
| SCHEMBL10227814 | 0.84 | LOXL2 (0.34) | LOXL2HRH3ADRB2ABAT | |
| SCHEMBL2600004 | 0.84 | HRH3 (0.50) | HRH3TAAR1 | |
| SCHEMBL12249672 | 0.84 | HRH3 (0.42) | LOXL2HRH3ADRB2RRM2ABAT | |
| SCHEMBL2642670 | 0.84 | ADRB2 (0.32) | LOXL2HRH3ADRB2ABAT | |
| SCHEMBL2643114 | 0.84 | PIK3CA (0.41) | LOXL2HRH3ADRB2RRM2ABAT | |
| SCHEMBL2691840 | 0.81 | HRH3 (0.44) | LOXL2HRH3ADRB2TAAR1 | |
| SCHEMBL13707710 | 0.79 | LOXL2 (0.34) | LOXL2TAAR1LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | claimed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | claimed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | claimed |
| EP-2943483-B1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-03-01 | — | — | EP | claimed |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-02-11 | — | — | US | claimed |
| EP-2943483-A1 | BENZYLAMINE DERIVATIVES | Kalvista Pharmaceuticals Limited (GB) | 2015-11-18 | — | — | EP | claimed |
| WO-2014108679-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-17 | — | — | WO | claimed |
| US-11472811-B2 | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | BEIGENE, LTD. (KY) | 2022-10-18 | — | — | US | disclosed |
| CN-112313234-B | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-07-01 | — | — | US | disclosed |
| CN-105143201-B | Benzyl amine derivative | 卡尔维斯塔制药有限公司 | 2019-02-22 | — | — | CN | disclosed |
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100016610-A1 | FRICTIONLESS MOLECULAR ROTARY MOTORS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-01-21 | — | — | US | disclosed |
| US-7629362-B2 | 2-pyridine carboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| WO-2008096360-A2 | FRICTIONLESS MOLECULAR ROTARY MOTORS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2008-08-14 | — | — | WO | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-3940441-A | BACTERICIDE | STERLING DRUG INC. (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | LOXL2 3952/4885HRH3 694/4885ADRB2 30/4885 |
| US-11472811-B2 | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | ADORA2A, ADORA3, ADORA2B | LOXL2 3952/4885HRH3 694/4885ADRB2 30/4885 |
| US-20100016610-A1 | FRICTIONLESS MOLECULAR ROTARY MOTORS | DYNLL2, ATXN2L, DYNLL1 | LOXL2 3736/4885HRH3 1958/4885ADRB2 3285/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | LOXL2 2252/4885HRH3 3819/4885ADRB2 1744/4885 |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | BDKRB1, BDKRB2, KLKB1 | LOXL2 2032/4885HRH3 36/4885ADRB2 345/4885 |
| US-20170253561-A1 | Benzylamine Derivatives | BDKRB1, BDKRB2, KLKB1 | LOXL2 2032/4885HRH3 36/4885ADRB2 345/4885 |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | LOXL2 2232/4885HRH3 3835/4885ADRB2 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.